FASN and neoplasm: Considering that C75 showed relevant side effects [97], another compound was developed to inhibit FASN, C93, which promoted a remarkable growth reduction in NSCLC orthotopic xenograft tumors [96] and prevented tumor growth in carcinogen-exposed mice [45].